$XBI $129.59 +3.83%
Covid Updates
$COCP +5.9% Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment. source
$NVAX +15.9% Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia. source
$NVAX +15.9% Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency. source
$MRNA -2.3% Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents. source
Pipeline Updates
$RYTM +5.1% Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021 source
$LEGN +0.4% Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel source
$MIRM +2.2% NEW LIVMARLI™ (MARALIXIBAT) DATA TO BE SHOWCASED AT AASLD THE LIVER MEETING® 2021 source
$ASMB +1.0% Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®. source
$AUPH -1.4% Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis. source
$INCY +3.5% Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting. source
$SRNE +2.8% Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer. source
$ATAI +6.4% atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia. source
$MBIO +6.3% Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas. source
$EIGR +4.6% Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV. source
$NBIX +0.8% Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021. source
$IMTX +0.4% Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting . source
$CMPI +8.5% Checkmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting. source
$SESN 0.0% Sesen Bio Announces Productive CMC Type A Meeting with the FDA. source
$BNTX -1.6% BioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting. source
$ACXP +9.4% Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference. source
$LPCN +1.9% Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021. source
$VBIV +5.2% VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021. source
$CHRS +1.5% Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma. source
$CNTA -18.6% Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874. source
$CALA +3.6% Calithera Presents Interim Data from Phase 1b trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021. source
$BLU -2.4% BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937. source
$SIOX +6.3% Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis. source
$INCY +3.5% Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas. source
$CABA +5.1% Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV. source
$DBVT +7.3% DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021. source
$HCM +2.3% HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma. source
Posted by FS/JM
Comments